Cargando…

Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib

The B-cell receptor signaling pathway has emerged as an important therapeutic target in chronic lymphocytic leukemia and other B-cell malignancies. Novel agents have been developed targeting the signaling enzymes spleen tyrosine kinase (SYK), Bruton’s tyrosine kinase, and phosphoinositide 3-kinase d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharman, Jeff, Di Paolo, Julie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2016
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872176/ https://www.ncbi.nlm.nih.gov/pubmed/27247756 http://dx.doi.org/10.1177/2040620716636542

Ejemplares similares

Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies
por: Kittai, Adam S., et al.
Publicado: (2021)

Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
por: Kutsch, Nadine, et al.
Publicado: (2022)

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma
por: Burke, John M., et al.
Publicado: (2018)

An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma
por: Andorsky, David J., et al.
Publicado: (2018)

Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia
por: Loftus, Joseph P., et al.
Publicado: (2020)

Precursor B-ALL Cell Lines Differentially Respond to SYK Inhibition by Entospletinib
por: Sender, Sina, et al.
Publicado: (2021)

Promises and pitfalls of targeted agents in chronic lymphocytic leukemia
por: Lew, Thomas E., et al.
Publicado: (2020)

Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma
por: Morschhauser, Franck, et al.
Publicado: (2020)

Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers
por: Ramanathan, Srini, et al.
Publicado: (2016)

The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance
por: Narayanan, Silpa, et al.
Publicado: (2021)

B-cell antigen receptor expression and phosphatidylinositol 3-kinase signaling regulate genesis and maintenance of mouse chronic lymphocytic leukemia
por: Schmid, Vera Kristin, et al.
Publicado: (2022)

Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling
por: Dielschneider, R F, et al.
Publicado: (2014)

Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target
por: Hartsink-Segers, S A, et al.
Publicado: (2013)

Constitutive Activation of the B Cell Receptor Underlies Dysfunctional Signaling in Chronic Lymphocytic Leukemia
por: Ziegler, Carly G.K., et al.
Publicado: (2019)

The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling
por: Lorenzo-Herrero, Seila, et al.
Publicado: (2019)

“Role of the B-cell receptor and the microenvironment in chronic lymphocytic leukemia''
por: Oppezzo, P, et al.
Publicado: (2013)

In vitro and in vivo evidence for uncoupling of B-cell receptor internalization and signaling in chronic lymphocytic leukemia
por: Coulter, Eve M., et al.
Publicado: (2018)

Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase
por: Aslan, Burcu, et al.
Publicado: (2021)

A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia
por: Smith, Audrey L., et al.
Publicado: (2022)

Phosphoinositide 3′-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia
por: Hoellenriegel, Julia, et al.
Publicado: (2011)

The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action
por: Chen, Rong, et al.
Publicado: (2021)

Targeted treatment for chronic lymphocytic leukemia
por: Masood, Aisha, et al.
Publicado: (2011)

Therapeutic Targets in Chronic Lymphocytic Leukemia
por: Laurenti, Luca, et al.
Publicado: (2020)

FcγRIIb-BCR coligation inhibits B-cell receptor signaling in chronic lymphocytic leukemia
por: Bosch, Rosa, et al.
Publicado: (2020)

B cell receptor isotypes differentially associate with cell signaling, kinetics, and outcome in chronic lymphocytic leukemia
por: Mazzarello, Andrea N., et al.
Publicado: (2022)

SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2
por: von Wenserski, Lisa, et al.
Publicado: (2020)

The Tyrosine Kinase Receptor ROR1 Is Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) Cells
por: Hojjat-Farsangi, Mohammad, et al.
Publicado: (2013)

Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia
por: Hojjat-Farsangi, Mohammad, et al.
Publicado: (2015)

Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia
por: Benkisser-Petersen, Marco, et al.
Publicado: (2016)

Siglec-6 is a Target for Chimeric Antigen Receptor T-cell Treatment of Chronic Lymphocytic Leukemia
por: Kovalovsky, Damian, et al.
Publicado: (2021)

Toll-like Receptors in Chronic Lymphocytic Leukemia
por: Muzio, Marta, et al.
Publicado: (2012)

TACI Expression and Signaling in Chronic Lymphocytic Leukemia
por: Mamara, Antigoni, et al.
Publicado: (2015)

Highlights: B-chronic lymphocytic leukemia: Current diagnostic characteristics of and treatments for chronic lymphocytic leukemia in Japan
por: Aoki, Sadao
Publicado: (2020)

The Expression of Toll-Like Receptors in Patients with B-Cell Chronic Lymphocytic Leukemia
por: Rybka, Justyna, et al.
Publicado: (2017)

Pathological RANK signaling in B cells drives autoimmunity and chronic lymphocytic leukemia
por: Alankus, Begüm, et al.
Publicado: (2020)

Targeting the tumor microenvironment in chronic lymphocytic leukemia
por: Svanberg, Rebecka, et al.
Publicado: (2021)

Targeting metabolic reprogramming in chronic lymphocytic leukemia
por: Nie, Yu, et al.
Publicado: (2022)

P645: IBRUTINIB FOR TREATMENT OF RELAPSED-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: A MATCHING-ADJUSTED INDIRECT COMPARISON OF 3 RANDOMIZED PHASE 3 TRIALS
por: Ghia, Paolo, et al.
Publicado: (2023)

Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia
Publicado: (1982)

Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia
por: Aslan, Burcu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9vpt7ukq1hhvk8gbmhguoakmgc